Gene editing company CRISPR Therapeutics (CRSP) made a basing pattern in the January-July time frame and the indicators support the potential for further price gains. Let's check out the charts.
More from Investing
Let's review three high-yield business development companies.
Here are six ways to handle the two biggest risks.
Some tech stocks now look like screaming bargains, while others still look expensive or appear to be value traps.
The hurt Fed Chair Jerome Powell has been talking about so much lately is no longer an abstract concept on Wall Street. But with the horrible action comes opportunities.